[Esaprazole vs sulglicotide in the treatment of dyspeptic patients with chronic superficial gastritis of the antrum].

Abstract

Fifty dyspeptic patients with histologically proven chronic superficial antral gastritis were treated for 6 weeks, in a randomized single-blind study, with esaprazole (450 mg bid) or sulglicotide (200 mg tid). Both drugs significantly improved the symptomatic score after 3 and 6 weeks (p less than 0.01), and the percentual rate of improvement was similar in the two groups studied. Similarly, both treatments significantly reduced the inflammation of gastric mucosa. Drugs were ineffective in clearing Helicobacter pylori from the antral mucosa (as assessed by the urease test, performed at entry and after 6 weeks). No side effects occurred after esaprazole or sulglicotide administration. The results of the present study suggest that esaprazole, a new gastroprotective drug, may have a role in the therapy of dyspeptic patients with chronic superficial gastritis.

• Authors: F Sabbatini, M Minieri, F Castiglione, E Di Lanno, G Mazzacca
• Journal: La Clinica terapeutica (Clin Ter) Vol. 137 Issue 2 Pg. 83-9 (Apr 30 1991) ISSN: 0009-9074 [Print] Italy
• Vernacular Title: Esaprazolo vs sulglicotide nel trattamento di pazienti dispeptici portatori di gastrite cronica superficiale dell'antro.
• PMID: 1828408 (Publication Type: Clinical Trial, Comparative Study, English Abstract, Journal Article, Randomized Controlled Trial)

Chemical References

• Anti-Ulcer Agents
• Piperazines
• Sialoglycoproteins
• sulglicotide
• esaprazole

Topics

• Adolescent
• Adult
• Anti-Ulcer Agents (therapeutic use)
• Chronic Disease
• Dyspepsia (drug therapy)
• Female
• Gastritis (drug therapy)
• Humans
• Male
• Middle Aged
• Piperazines (therapeutic use)
• Pyloric Antrum
• Sialoglycoproteins (therapeutic use)
• Single-Blind Method